Evidence map›Paper›PMID 42129101›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Combination of Fc-Protein Engineering Strategies: Design and Evaluation of Antibody Effector Functions.

Carina Lynn Gehlert, Steffen Krohn, Dorothee Winterberg, Ammelie Svea Boje, Thomas Theocharis, Alexander Jochimsen, Marta Lustig, Thomas Valerius, Christian Kellner, Katja Klausz and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Carina Lynn GehlertDivision of Antibody-Based Immunotherapy, Department of Internal Medicine II, Kiel University and University Hospital Schleswig-Holstein, Campus Kiel, Germany.
Steffen KrohnDivision of Antibody-Based Immunotherapy, Department of Internal Medicine II, Kiel University and University Hospital Schleswig-Holstein, Campus Kiel, Germany.
Dorothee WinterbergDivision of Antibody-Based Immunotherapy, Department of Internal Medicine II, Kiel University and University Hospital Schleswig-Holstein, Campus Kiel, Germany.
Ammelie Svea BojeDivision of Antibody-Based Immunotherapy, Department of Internal Medicine II, Kiel University and University Hospital Schleswig-Holstein, Campus Kiel, Germany.
Thomas TheocharisDivision of Antibody-Based Immunotherapy, Department of Internal Medicine II, Kiel University and University Hospital Schleswig-Holstein, Campus Kiel, Germany.
Alexander JochimsenDivision of Antibody-Based Immunotherapy, Department of Internal Medicine II, Kiel University and University Hospital Schleswig-Holstein, Campus Kiel, Germany.
Marta LustigDivision of Stem Cell Transplantation and Cellular Immunotherapy Department of Internal Medicine II, Kiel University and University Hospital Schleswig-Holstein, Campus Kiel, Germany.
Thomas ValeriusDivision of Stem Cell Transplantation and Cellular Immunotherapy Department of Internal Medicine II, Kiel University and University Hospital Schleswig-Holstein, Campus Kiel, Germany.
Christian KellnerDivision of Transfusion Medicine, Cell Therapeutics and Haemostaseology, University Hospital, LMU Munich, Munich, Germany.
Katja KlauszDivision of Antibody-Based Immunotherapy, Department of Internal Medicine II, Kiel University and University Hospital Schleswig-Holstein, Campus Kiel, Germany.
Matthias PeippDivision of Antibody-Based Immunotherapy, Department of Internal Medicine II, Kiel University and University Hospital Schleswig-Holstein, Campus Kiel, Germany. m.peipp@med2.uni-kiel.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal antibodies have revolutionized cancer therapy and are integral part of standard therapies. Despite their clinical efficacy, not all cancer patients benefit from established antibody therapies. Preclinical and clinical findings revealed that Fc-mediated effector functions play an essential role in antibody therapy. Therefore, current antibody-based immunotherapies can be optimized by antibody Fc engineering to generate next-generation monoclonal antibodies with tailor-made effector functions. The enhancement of Fc-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) may increase efficiency of prospective antibody-based immunotherapies.

Indexed as

Antibodies, MonoclonalImmunoglobulin Fc FragmentsProtein EngineeringAnimalsAntibody-Dependent Cell CytotoxicityHumansImmunotherapyPhagocytosisAntibodies, MonoclonalImmunoglobulin Fc FragmentsADCCADCPAntibody therapyCDCFc engineering

Identifiers

PMID42129101

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.